Galectin Therapeutics Q1 EPS $(0.15) Beats $(0.20) Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings BeatsNews
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.20) by 25 percent. This is a 21.05 percent increase over losses of $(0.19) per share
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.20) by 25 percent. This is a 21.05 percent increase over losses of $(0.19) per share from the same period last year.